<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03222531</url>
  </required_header>
  <id_info>
    <org_study_id>PRO17020069</org_study_id>
    <nct_id>NCT03222531</nct_id>
  </id_info>
  <brief_title>Expanding the Pool in Orthotopic Heart Transplantation</brief_title>
  <official_title>Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To perform a study (100 patients) utilizing Hepatitis C positive donor hearts for hepatitis C
      negative donors with post-operative surveillance and treatment only if a recipient infection
      occurs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators are proposing a proof of concept study in which positive donors will be
      used for HCV negative patients. Following heart transplantation patients will undergo HCV
      antibody, virus PCR, and liver function testing. Recipients whom test positive for HCV
      viremia for 2 consecutive tests at any point will complete 12 weeks of Sofosbuvir/velpatasvir
      therapy.

      This initial study would enroll 100 patients and utilize donors that are young, otherwise
      healthy, with normal biventricular heart function whom are Hepatitis C antibody positive but
      Nucleic Acid Amplification Testing (NAT) negative (HCV Ab+/NAT-). The recipients would be
      limited to those patients who have previously consented to receive a high risk heart
      transplant, consented to participant in this study, and who are physiologically optimized for
      transplantation (e.g., low risk for heart transplantation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>HCV Viremia</measure>
    <time_frame>at 2 years</time_frame>
    <description>Incidence of HCV Viremia</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>at 2 years</time_frame>
    <description>Rate of HCV seroconversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Testing</measure>
    <time_frame>at 2 years</time_frame>
    <description>Assessment of Hepatic function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>at 2 years</time_frame>
    <description>Survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rejection</measure>
    <time_frame>at 2 years</time_frame>
    <description>The incidence of rejection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waitlist</measure>
    <time_frame>at 2 years</time_frame>
    <description>Time on waitlist will be assessed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>at 2 years</time_frame>
    <description>Echocardiography will be used to assess for ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Catheterization</measure>
    <time_frame>at 2 years</time_frame>
    <description>Cardiac Catheterization be utilized to determine vasculopathy when appropriate</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Heart Transplant</condition>
  <condition>Cardiac Transplant</condition>
  <arm_group>
    <arm_group_label>Heart Transplant</arm_group_label>
    <description>Patients will be transplanted with HCV positive heart. Recipients whom test positive for HCV viremia for 2 consecutive tests at any point will complete 12 weeks of Epclusa (Sofosbuvir/velpatasvir).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Heart Transplant</intervention_name>
    <description>Hepatitis C positive heart transplant into hepatitis C negative patients</description>
    <arm_group_label>Heart Transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epclusa</intervention_name>
    <description>Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.</description>
    <arm_group_label>Heart Transplant</arm_group_label>
    <other_name>Sofosbuvir/velpatasvir</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Transplanted patients that would seroconvert from the Hep C positive antibody organ given
        at transplant.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Patients who sign the informed consent for this study

          -  Patients whom agree to receive a PHS high risk organ

          -  Patients listed for heart transplantation listed as Status 1A, 1B, or 2 who have
             signed informed consent for heart transplantation

             1A top priority -- critically ill, requiring placement of invasive monitoring,
             intravenous medications or a temporary support pump. Some patients may also be this
             status if they have a mechanical assist device (heart pump).

               1. B - require special intravenous medications (inotropes) to help the heart
                  function adequately while waiting either in the hospital or at home or be
                  supported without complications on a mechanical assist device (heart pump)

               2. - does not require special intravenous medications to maintain adequate heart
                  function - usually waiting at home

          -  Age 18-65

        Exclusion Criteria

          -  Patients who do not sign informed consent for this study

          -  HIV Seropositivity

          -  HBV Seropositivity (HBcAb and/or HBsAg positive)

          -  Abnormal liver enzymes - 3 times the normal liver function values (Bilirubin, INR,
             AST, ALT)

          -  Acute or chronic renal insufficiency (creatinine clearance &lt;50 ml/min) or history of
             dialysis

          -  Patients on ECMO or temporary left or right heart mechanical support. Specifically,
             impella , or temporary not durable/implantable LVAD and/or RVAD

          -  Severe cardiogenic shock

               -  &gt;1 inotrope

               -  ECMO

               -  LVAD and inotropic therapy

               -  Inotrope with temporary mechanical support (intra-aortic balloon pump or Impella)

          -  Respiratory insufficiency requiring mechanical respiratory support (ventilator, BiPAP)

          -  Liver insufficiency (MELD &gt;19)

          -  Prior history of hepatitis C

          -  Allergy to Sofosbuvir/velpatasvir

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christopher Sciortino, MD</last_name>
    <phone>412-648-3202</phone>
    <email>sciortinocm@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Shullo, PharmD</last_name>
    <phone>412-802-3131</phone>
    <email>shulloma@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Sciortino, MD</last_name>
      <phone>412-647-6636</phone>
      <email>sciortinocm@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Sciortino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Christopher Sciortino</investigator_full_name>
    <investigator_title>Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

